Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 23:52:40·⟳ 抓取 23:53:12 +32s·⚡ 决策 10-16 23:54:51 +1m39s·10.9 天前
ImmunityBio 公布 ANKTIVA 膀胱癌 QUILT-3.032 长期随访数据，但核心结果与 papillary 适应症扩展均为已披露旧闻
本条信号是 Investing.com AI 生成稿，转述的 71% CR/26.6 个月数据在 2022 年与 2025 年 AUA 已公开，唯一真正的增量——FDA 扩展 papillary-only 适应症——已在 2026-10-14 由公司与 SEC 披露并消化 2 个交易日；期刊发表不改变临床或监管状态，无预期差与 edge，且无净利空故不做空。
📄 原文Investing.com↗ 原文
ImmunityBio reports long-term bladder cancer treatment data
Goldman flags 2 memory stocks to buy amid deeper sector pullback CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ:IBRX)…
不做 ImmunityBio, Inc.（IBRX.US）
无增量事实：71% CR 等 QUILT-3.032 数据 2022 年已公布、5 年随访 2025 AUA 已展示，本次仅为期刊同行评审发表；唯一实质增量 papillary 适应症 FDA 扩展已于 2026-10-14 官方披露并过 2 个交易日，信号时股价 -5.9% 显示无正向重定价；数据偏正面亦无做空催化，故双向不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ANKTIVA 长期随访数据积极但非新读出（71% CR 自 2022 年已知、5 年随访 2025 AUA 已展示），真正的监管增量 papillary 适应症扩展已于 10-14 官方宣布；本条聚合稿无新增事实，IBRX 盘中反而下跌约 6%，不参与。
消息传播链
- 聚合改写稿，转述 Journal of Urology 发表的 QUILT-3.032 长期数据；非一手数据首发。市场反应:信号时 IBRX 盘中 9.41 美元，当日 -5.9%，未见正向重定价。
关键理由
- 名义正面：长期随访显示疗效持久（CR 中位 26.6 个月、3 年 DSS 98.2%）且安全性良好，支撑已上市产品的商业化叙事。
主要风险
- 若市场把期刊发表误读为新催化而短线拉升，属低质量情绪波动，追高风险大；公司仍亏损（PE TTM 为负），后续 BCG-naïve sBLA 与 PDUFA（2027-01-06）才是实质节点。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-14 · 影响 invalidates
监管增量 10-14 已官方落地、临床数据 2022/2025 已披露，做多缺乏新预期差；股价盘中 -5.9%、近 20 日仍 +18%，无低位抢跑式错杀证据。
检索:ImmunityBio ANKTIVA papillary FDA approval date October 2026 / QUILT-3.032 data previously presented 原文 ↗ - 做空前查反向 · 来源 web · 影响 invalidates
未发现与本事件相关的新安全性、监管或商业化利空；数据本身积极，盘中下跌更可能随板块/获利回吐，不满足做空红线。
检索:ImmunityBio ANKTIVA safety signal label update clinical hold October 2026
先例如何影响了这次决策
对本次决策的影响:先例不改变结论；核心依据为事件身份（旧数据期刊落地＋监管增量已提前披露）而非涨幅统计。
方向:未做外部先例定价：本条因缺少增量事实而回避，幅度校准无意义。
涨幅量级:无可用于校准的新催化相位先例。
形态:不适用；期刊发表旧数据＋2 天前监管批准的组合通常无新增价格反应，本次盘中 -5.9% 与此一致。
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`ibrx anktiva bcg-unresponsive nmibc complete response 71% | immunitybio anktiva quilt-3.032 long-term bladder cancer journal of urology | immunitybio fda expanded indication papill`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 1 ms
{ - stock_quote 成功 stock_tools HTTP · 215 ms
{ - web_search 成功 doubao_search · 1,340 ms
豆包搜索结果（原始查询:ImmunityBio ANKTIVA QUILT-3.032 long-term data Journal of Urology publication press release；API SearchType:web） - web_search 成功 doubao_search · 1,445 ms
豆包搜索结果（原始查询:ImmunityBio ANKTIVA FDA approval papillary-only NMIBC October 2026 expanded indication；API SearchType:web）
原文全文
展开原文 · 2,163 字
Goldman flags 2 memory stocks to buy amid deeper sector pullback
CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ:IBRX) announced the publication of long-term data from its Phase 2/3 QUILT-3.032 study in the Journal of Urology, according to a press release statement. The study evaluated ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) in 100 patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary disease.
The study reported a 71% complete response rate in patients with BCG-unresponsive non-muscle invasive bladder cancer. The median duration of complete response was 26.6 months, with some responses extending beyond 53 months. More than half of responding patients in the FDA-reviewed population maintained complete responses beyond 45 months.
Among responders, 84% achieved cystectomy-free survival at 36 months. Disease-specific survival reached 98.2% at three years. The study showed 63.8% of responders maintained complete response for at least 12 months, 52.3% for at least 24 months, and 44.2% for at least 36 months. Progression-free survival remained 80.9% at three years.
In BCG refractory patients who never responded to prior treatment, the complete response rate was 66%. Four percent of responders progressed to muscle-invasive disease.
The treatment demonstrated no Grade 4 or Grade 5 treatment-related adverse events. Most treatment-related adverse events were Grade 1 or Grade 2, consisting of localized bladder symptoms. Grade 3 treatment-related adverse events occurred in 4% of patients.
ANKTIVA received FDA approval in 2024 for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. This month, the FDA expanded the approved indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease.
The QUILT-3.032 study represents one of the longest follow-up datasets reported in this disease setting, with outcomes extending beyond five years in some patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ:IBRX) announced the publication of long-term data from its Phase 2/3 QUILT-3.032 study in the Journal of Urology, according to a press release statement. The study evaluated ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) in 100 patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary disease.
The study reported a 71% complete response rate in patients with BCG-unresponsive non-muscle invasive bladder cancer. The median duration of complete response was 26.6 months, with some responses extending beyond 53 months. More than half of responding patients in the FDA-reviewed population maintained complete responses beyond 45 months.
Among responders, 84% achieved cystectomy-free survival at 36 months. Disease-specific survival reached 98.2% at three years. The study showed 63.8% of responders maintained complete response for at least 12 months, 52.3% for at least 24 months, and 44.2% for at least 36 months. Progression-free survival remained 80.9% at three years.
In BCG refractory patients who never responded to prior treatment, the complete response rate was 66%. Four percent of responders progressed to muscle-invasive disease.
The treatment demonstrated no Grade 4 or Grade 5 treatment-related adverse events. Most treatment-related adverse events were Grade 1 or Grade 2, consisting of localized bladder symptoms. Grade 3 treatment-related adverse events occurred in 4% of patients.
ANKTIVA received FDA approval in 2024 for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. This month, the FDA expanded the approved indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease.
The QUILT-3.032 study represents one of the longest follow-up datasets reported in this disease setting, with outcomes extending beyond five years in some patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8785d041d9· 2026-10-16 23:54 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前